Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review

Current and future therapeutic approaches for osteosarcoma

Harrison, D. J., Geller, D. S., Gill, J. B., Lewis, V. O., & Gorlick, R. G. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 688 · see citing works

Osteosarcoma: a comprehensive review

Misaghi, A., Goldin, A. N., Awad, M. A. H., & Kulidjian, A. (2018) · SICOT-J · doi:10.1051/sicotj/2017028 · Cited by 522 · see citing works

Review of Osteosarcoma and Current Management

Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 397 · see citing works

Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey

Hoffman, R. M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.963050 · Cited by 195 · see citing works

Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide

Bacci, G., Briccoli, A., Rocca, M., Ferrari, S., Donati, D. M., Longhi, A., Bertoni, F., Bacchini, P., Giacomini, S., Forni, C., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg286 · Cited by 187 · see citing works

DNA Hypomethylating Drugs in Cancer TherapyPreprint

Sato, T., Issa, J. J., & Kropf, P. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026948 · Cited by 166 · see citing works

Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials

Gelderblom, H. A. J., Jinks, R. C., Sydes, M. R., Bramwell, V. H. C., Glabbeke, M. M. V., Grimer, R. J., Hogendoorn, P. C. W., McTiernan, A., Lewis, I. J., Nooij, M. A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.036 · Cited by 133 · see citing works

Current and Emerging Targets in Immunotherapy for Osteosarcoma

Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · Journal of Oncology · doi:10.1155/2019/7035045 · Cited by 123 · see citing works

Establishment of a Patient-Derived Orthotopic Xenograft (PDOX) Model of HER-2-Positive Cervical Cancer Expressing the Clinical Metastatic Pattern

Hiroshima, Y., Zhang, Y., Zhang, N., Maawy, A. A., Mii, S., Yamamoto, M., Uehara, F., Miwa, S., Yano, S., Murakami, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117417 · Cited by 113 · see citing works

Metastatic Recurrence in a Pancreatic Cancer Patient Derived Orthotopic Xenograft (PDOX) Nude Mouse Model Is Inhibited by Neoadjuvant Chemotherapy in Combination with Fluorescence-Guided Surgery with an Anti-CA 19-9-Conjugated Fluorophore

Hiroshima, Y., Maawy, A. A., Zhang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114310 · Cited by 91 · see citing works

Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer

Kawaguchi, K., Miyake, K., Han, Q., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.016 · Cited by 87 · see citing works

Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic

Igarashi, K., Kawaguchi, K., Kiyuna, T., Miyake, K., Miyake, M., Li, S., Han, Q., Tan, Y., Zhao, M. D., Li, Y., et al. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1431596 · Cited by 75 · see citing works

Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model

Higuchi, T., Kawaguchi, K., Miyake, K., Han, Q., TAN, Y., Oshiro, H., Sugisawa, N., ZHANG, Z., Razmjooei, S., Yamamoto, N., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12899 · Cited by 73 · see citing works

Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy

Hiroshima, Y., Maawy, A. A., Zhang, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12322 · Cited by 61 · see citing works

Intra-arterial administration of tumor-targetingSalmonella typhimuriumA1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model

Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Nelson, S. D., Dry, S., Li, Y., Yanagawa, J., Russell, T. A., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1317417 · Cited by 54 · see citing works

A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology

Igarashi, K., Murakami, T., Kawaguchi, K., Kiyuna, T., Miyake, K., Zhang, Y., Nelson, S. D., Dry, S., Li, Y., Yanagawa, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19095 · Cited by 54 · see citing works

Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review

Kawaguchi, K., Han, Q., Li, S., et al. (2019) · Cells · doi:10.3390/cells8050410 · Cited by 52 · see citing works

Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma

Higuchi, T., Oshiro, H., Miyake, K., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13646 · Cited by 49 · see citing works

PPARγ agonists: potential treatment for autism spectrum disorder by inhibiting the canonical WNT/β-catenin pathway

Vallée, A., Vallée, J.-N., & Lecarpentier, Y. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0131-4 · Cited by 44 · see citing works

The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model

Higuchi, T., Sugisawa, N., Yamamoto, J., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03986-0 · Cited by 43 · see citing works

Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model

Higuchi, T., Miyake, K., Oshiro, H., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.191 · Cited by 42 · see citing works

Prognostic Value of Histological Response to Chemotherapy in Osteosarcoma Patients Receiving Tumor-Bearing Frozen Autograft

Miwa, S., Takeuchi, A., Ikeda, H., Shirai, T., Yamamoto, N., Nishida, H., Hayashi, K., Tanzawa, Y., Kimura, H. J., Igarashi, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071362 · Cited by 41 · see citing works

Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression

Higuchi, T., Sugisawa, N., Miyake, K., Oshiro, H., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Igarashi, K., Kline, Z., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109356 · Cited by 37 · see citing works

PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model

Higuchi, T., Yamamoto, J., Sugisawa, N., et al. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20165 · Cited by 35 · see citing works

Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model

Higuchi, T., Sugisawa, N., Miyake, K., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13565 · Cited by 34 · see citing works

Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma

Hoffman, R. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091875 · Cited by 33 · see citing works

Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model

Higuchi, T., Sugisawa, N., Miyake, K., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13662 · Cited by 32 · see citing works

Efficacy of Tumor-Targeting Salmonella typhimurium A1-R against Malignancies in Patient-Derived Orthotopic Xenograft (PDOX) Murine Models

Murakami, T., Hiroshima, Y., Miyake, K., Kiyuna, T., Endo, I., Zhao, M. D., & Hoffman, R. M. (2019) · Cells · doi:10.3390/cells8060599 · Cited by 30 · see citing works

Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model

AOKI, Y., Tome, Y., WU, N. F., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.14939 · Cited by 26 · see citing works

Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model

Igarashi, K., Kawaguchi, K., Kiyuna, T., Miyake, K., Miyake, M., Li, Y., Nelson, S. D., Dry, S., Singh, A. S., Elliott, I. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22892 · Cited by 25 · see citing works

Anti‐tumor effects of a nonsteroidal anti‐inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator‐activated receptor gamma and suppressing matrix metalloproteinase‐2 expression

Higuchi, T., Takeuchi, A., Munesue, S., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1438 · Cited by 25 · see citing works

The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model

Higuchi, T., Sugisawa, N., Miyake, K., Oshiro, H., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Igarashi, K., Bouvet, M., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.06.002 · Cited by 25 · see citing works

Dynamic color-coded fluorescence imaging of the cell-cycle phase, mitosis, and apoptosis demonstrates how caffeine modulates cisplatinum efficacy

Miwa, S., Yano, S., Tome, Y., Sugimoto, N., Hiroshima, Y., Uehara, F., Mii, S., Kimura, H. J., Hayashi, K., Efimova, E. V., et al. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24593 · Cited by 23 · see citing works

Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model

Kiyuna, T., Tome, Y., Miyake, K., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13661 · Cited by 21 · see citing works

An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model

Oshiro, H., Tome, Y., Miyake, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87553-9 · Cited by 21 · see citing works

Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model

Miyake, K., Kiyuna, T., Kawaguchi, K., Higuchi, T., Oshiro, H., Zhang, Z., Wangsiricharoen, S., Razmjooei, S., Li, Y., Nelson, S. D., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03782-w · Cited by 20 · see citing works

PPARγ-dependent anti-tumor and immunomodulatory actions of pioglitazone

El‐Sisi, A. E., Sokar, S. S., Salem, T., et al. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2014.978055 · Cited by 12 · see citing works

A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model

Igarashi, K., Kawaguchi, K., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Higuchi, T., Taniguchi, Y., Yonezawa, H., Araki, Y., et al. (2020) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20182 · Cited by 11 · see citing works

Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib

Higuchi, T., Igarashi, K., Yamamoto, N., et al. (2021) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20286 · Cited by 11 · see citing works

Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model

WU, N. F., Yamamoto, J., AOKI, Y., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.14943 · Cited by 7 · see citing works

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

Schöffski, P., Dumez, H., Wolter, P., Stefan, C., Woźniak, A., Jimeno, J. M., & van Oosterom, A. T. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1609 · Cited by 58 · see citing works

Trabectedin for the management of soft-tissue sarcoma

Boudou, L., Baconnier, M., Blay, J., et al. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.28 · Cited by 7 · see citing works

Regorafenib Improves OS in Asian Patients with mCRC after Previous Failure with Standard Therapy

Mosley, M., & Li, J. (2014) · MD Conference Express · doi:10.1177/155989771422015

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence

Ferrandina, G., Mascilini, F., Amadio, G., Stefano, M. G. D., Legge, A. D., Vincenzo, R. D., Masciullo, V., Salutari, V., Scambia, G., Conte, C., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s51550 · Cited by 14 · see citing works

Regorafenib: A Review in Metastatic Colorectal Cancer

Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0938-y · Cited by 90 · see citing works